Hengrui Pharmaceutical announced that Shandong Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received the HRS-5346 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to conduct phase III clinical trials. The application is to reduce the risk of major adverse cardiovascular events in adult patients with confirmed atherosclerotic cardiovascular disease accompanied by elevated lipoprotein or increased risk of the first cardiovascular event. HRS-5346 is an oral small molecule inhibitor of LP. Currently, no similar drug has been approved for marketing at home or abroad, and the total R&D investment for related projects is about 86.2 million yuan. The drug still needs to complete clinical trials and pass review and approval before it can be marketed. There is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.